Potential benefits of MOTS-c: Improved insulin sensitivity Better glucose control Increased exercise capacity Enhanced mitochondrial function Improved metabolic flexibility Unlike Semaglutide or Tirzepatide, MOTS-c does not primarily work by reducing appetite
The ICD-10-CM code list above is not exhaustive
Store the product in a cool, dry place away from direct sunlight to preserve its potency
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Even meat-eaters can become deficient if they have poor methylation, high stress, or chronic fatigue